 Janus Kinase 2
"Janus Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
| Descriptor ID |
D053614
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.200 D12.776.476.393.200 D12.776.624.664.700.117
|
| Concept/Terms |
Janus Kinase 2- Janus Kinase 2
- JAK2 Protein Tyrosine Kinase
- JAK-2 Protein Tyrosine Kinase
- JAK 2 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 2".
This graph shows the total number of publications written about "Janus Kinase 2" by people in UAMS Profiles by year, and whether "Janus Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 2 | 2 | | 2022 | 0 | 1 | 1 | | 2021 | 1 | 1 | 2 | | 2018 | 1 | 1 | 2 | | 2017 | 1 | 0 | 1 | | 2013 | 0 | 2 | 2 | | 2012 | 1 | 0 | 1 | | 2011 | 1 | 2 | 3 | | 2008 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2006 | 1 | 2 | 3 | | 2003 | 0 | 2 | 2 | | 1998 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Janus Kinase 2" by people in Profiles over the past ten years.
-
Zhang B, Li B, Xie Y, Chang S, Xu Z, Hu H, Chen G, Zhang T, He J, Wu X, Zhu H, Lai W, Song D, Lu Y, Jia X, Zhu W, Shi J. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway. Acta Biochim Biophys Sin (Shanghai). 2023 Feb 25; 55(2):215-224.
-
Al-Ghamdi YA, Lake J, Bagg A, Thakral B, Wang SA, Bueso-Ramos C, Masarova L, Verstovsek S, Rogers HJ, Hsi ED, Gralewski JH, Chabot-Richards D, George TI, Rets A, Hasserjian RP, Weinberg OK, Parilla M, Arber DA, Padilla O, Orazi A, Tam W. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
-
Yenwongfai LN, Arora R, Smith AP, Kalfa T, Husami A, Radulescu V, Myers K, Lorsbach R. Pediatric myelofibrosis due to compound heterozygous MPIG6B mutations in a patient of European ancestry. Pediatr Blood Cancer. 2023 03; 70(3):e30023.
-
Reed MR, Lyle AG, De Loose A, Maddukuri L, Learned K, Beale HC, Kephart ET, Cheney A, van den Bout A, Lee MP, Hundley KN, Smith AM, DesRochers TM, Vibat CRT, Gokden M, Salama S, Wardell CP, Eoff RL, Vaske OM, Rodriguez A. A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. Cells. 2021 12 02; 10(12).
-
Yan B, Freiwald T, Chauss D, Wang L, West E, Mirabelli C, Zhang CJ, Nichols EM, Malik N, Gregory R, Bantscheff M, Ghidelli-Disse S, Kolev M, Frum T, Spence JR, Sexton JZ, Alysandratos KD, Kotton DN, Pittaluga S, Bibby J, Niyonzima N, Olson MR, Kordasti S, Portilla D, Wobus CE, Laurence A, Lionakis MS, Kemper C, Afzali B, Kazemian M. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Sci Immunol. 2021 04 07; 6(58).
-
Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018 07 02; 128(7):3041-3052.
-
Perissinotti PP, Rivero-Echeto MC, Garcia-Rill E, Bisagno V, Urbano FJ. Leptin alters somatosensory thalamic networks by decreasing gaba release from reticular thalamic nucleus and action potential frequency at ventrobasal neurons. Brain Struct Funct. 2018 Jun; 223(5):2499-2514.
-
de Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson LFG, de Carvalho MF, Braga WMT, Davies FE, Colleoni GWB. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. Cancer Lett. 2017 09 10; 403:206-215.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|